Company intelligence
BioMed X
BioMed X is a build-to-solve innovation engine for pharma, patient-focused foundations, and investors.
About BioMed X
BioMed X is a leading innovation engine where disruptive ideas in biomedical research and development come to life. With our global network of research institutes and venture-creating incubators, embedded within major innovation hubs, we bridge the gap between academic research and the needs of the pharmaceutical industry. We are pioneers in applying the principles of design thinking and crowdsourcing to drug discovery and development. With our unique model, we partner with pharma, venture capital, and patient-focused foundations to identify key challenges across all therapeutic areas, recruit top talent, and co-create tailored solutions. In our stimulating ecosystem, talented researchers from all around the globe grow into industry-ready scientific leaders. They perform exploratory research, deliver industry-grade results, and pave the way for next-generation therapies. At BioMed X, we value curiosity, diversity, and purpose. Together, we serve as a vital catalyst for innovation in global health - for the benefit of all patients.
Verified activity
Signals from BioMed X
5 published signals
Presence & Recognition
BioMed X is hosting a new session of the LunchTalk series on tracking mobile DNA from microbial ecosystems to individual bacterial hosts.
Reported by BioMed X
Partnerships
BioMed X community gathered with representatives from Boehringer Ingelheim for a farewell celebration marking the completion of the TeamBDB project
Reported by BioMed X
Partnerships
BioMed X announced the launch of a global partnership with BioLabs, a leading provider of shared laboratory infrastructure for life science innovators.
Reported by BioMed X
Operations & Supply
BioMed X Heidelberg will relocate its Global Headquarters to the brand-new LAB22 located in the same building as BioLabs Heidelberg, located in the same building.
Reported by BioMed X
Partnerships
BioMed X started a collaboration with Johannes Fruehauf and the entire BioLabs team.
Reported by Christian Tidona